Cara Therapeutics, Inc. (NASDAQ:CARA) Weekly Ratings as of May 3, 2018

May 3, 2018 - By Carey Conley

Cara Therapeutics, Inc. (NASDAQ:CARA) Corporate Logo
During 2017 Q4 the big money sentiment increased to 0.93. That’s change of 0.08, from 2017Q3’s 0.85. 16 investors sold all, 28 reduced holdings as Cara Therapeutics, Inc. ratio improved. 20 rose holdings while 21 funds acquired holdings. Funds hold 15.80 million shares thus 11.38% less from 2017Q3’s 17.83 million shares.
Parametric Portfolio Ltd Llc stated it has 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). National Bank Of Montreal Can accumulated 63,505 shs. Legal And General Group Pcl accumulated 7,064 shs or 0% of the stock. Dafna Capital Ltd holds 93,800 shs. Metropolitan Life Com owns 8,685 shs for 0% of their capital. Voya Lc holds 0% in Cara Therapeutics, Inc. (NASDAQ:CARA) or 12,316 shs. 100 were accumulated by Us National Bank & Trust De. Jefferies Grp Ltd Company owns 21,500 shs. Great West Life Assurance Com Can has 2,700 shs. Citigroup, New York-based fund reported 13,661 shs. Franklin Resources, a California-based fund reported 450,500 shs. Jpmorgan Chase And Co accumulated 354,865 shs. Bank & Trust Of Ny Mellon reported 0% of its capital in Cara Therapeutics, Inc. (NASDAQ:CARA). Proshare Advsr Ltd Llc invested 0% of its capital in Cara Therapeutics, Inc. (NASDAQ:CARA). Perigon Wealth Mngmt Ltd Liability Corporation has 0% invested in Cara Therapeutics, Inc. (NASDAQ:CARA) for 60 shs.

Cara Therapeutics, Inc. had 4 selling transactions and 0 buys since January 24, 2018. This’s net activity of $538,560. Menzaghi Frederique Ph.D. also sold $45,060 worth of Cara Therapeutics, Inc. (NASDAQ:CARA) shs.

Cara Therapeutics, Inc. (NASDAQ:CARA) Ratings Coverage

In total 5 analysts cover Cara Therapeutics (NASDAQ:CARA). “Buy” rating has 5, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 6 are the (NASDAQ:CARA)’s analyst reports since January 2, 2018 according to StockzIntelligence Inc. On Monday, March 19 the rating was maintained by H.C. Wainwright with “Buy”. On Monday, February 12 the firm earned “Buy” rating by Janney Capital. On Monday, March 12 the rating was reinitiated by H.C. Wainwright with “Buy”. On Tuesday, January 2 the rating was maintained by Stifel Nicolaus with “Buy”. On Thursday, March 15 Canaccord Genuity maintained the shares of CARA in report with “Buy” rating. Listed here are Cara Therapeutics, Inc. (NASDAQ:CARA) PTs and latest ratings.

19/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $22.0 Maintain
15/03/2018 Broker: Canaccord Genuity Rating: Buy New Target: $22.0 Maintain
12/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $22 Reinitiate
12/02/2018 Broker: Janney Capital Old Rating: Neutral New Rating: Buy Old Target: $21 Upgrade
19/01/2018 Broker: Seaport Global Rating: Buy New Target: $27 Initiates Coverage On
02/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $17.0 Maintain

The stock decreased 0.95% or $0.12 during the last trading session, hitting $12.45.Cara Therapeutics, Inc. has volume of 173,560 shares. Since May 3, 2017 CARA has declined 32.45% and is downtrending. CARA underperformed the S&P500 by 44.00%.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States.The firm is valued at $407.11 million. It is developing product candidates that target the body's peripheral nervous system.Last it reported negative earnings. The companyÂ’s lead product candidate comprises I.V.

Cara Therapeutics, Inc. (NASDAQ:CARA) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: